Celldex Therapeutics CLDX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $866K-44.0% | $1.55M-40.5% | $2.6M-55.1% | $5.79M-23.4% | $7.56M+7.7% | ||
| $265.46M+8.3% | $245.07M+13.1% | $216.68M+8.9% | $199.01M+7.9% | $184.5M+12.8% | ||
| $44.47M+1.4% | $43.84M+4.0% | $42.16M+1.5% | $41.53M+3.1% | $40.27M+4.5% | ||
| $3.37M-0.4% | $3.38M-0.1% | $3.38M+1.1% | $3.35M+2.3% | $3.27M+2.9% | ||
| $309.93M+7.3% | $288.91M+11.6% | $258.84M+7.6% | $240.54M+7.0% | $224.77M+11.2% | ||
| -$309.06M-7.5% | -$287.37M-12.1% | -$256.24M-9.2% | -$234.75M-8.1% | -$217.21M-11.3% | ||
| -35,688.5%-17,101pp | -18,587.7%-8,732pp | -9,855.4%-5,802pp | -4,053.7%-1,180pp | -2,873.5%-94.6pp | ||
| $25.42M-11.2% | $28.61M-9.8% | $31.71M-9.8% | $35.14M-8.4% | $38.36M+3.1% | ||
| -$283.65M-9.6% | -$258.76M-15.2% | -$224.53M-12.5% | -$199.61M-11.6% | -$178.85M-13.3% | ||
| -32,753.6%-16,016pp | -16,737.2%-8,101pp | -8,635.8%-5,189pp | -3,446.9%-1,081pp | -2,366.1%-117pp | ||
| -$4.27-9.5% | -$3.90-15.4% | -$3.38-12.3% | -$3.01-11.5% | -$2.70-10.2% | ||
| -$4.27-9.5% | -$3.90-15.4% | -$3.38-12.3% | -$3.01-11.5% | -$2.70-10.2% | ||
| 265.8M+0.1% | 265.6M+0.8% | 263.6M0.0% | 263.5M+0.1% | 263.1M+2.9% | ||
| 265.8M+0.1% | 265.6M+0.8% | 263.6M0.0% | 263.5M+0.1% | 263.1M+2.9% | ||
| -$284.69M-10.2% | -$258.45M-14.3% | -$226.06M-14.1% | -$198.05M-11.6% | -$177.53M-12.5% | ||
| $25.42M-11.2% | $28.61M-9.8% | $31.71M-9.8% | $35.14M-8.4% | $38.36M+3.1% | ||
| —— | —— | —— | —— | —— | ||
| $866K-44.0% | $1.55M-40.5% | $2.6M-55.1% | $5.79M-23.4% | $7.56M+7.7% | ||
| -$309.06M-7.5% | -$287.37M-12.1% | -$256.24M-9.2% | -$234.75M-8.1% | -$217.21M-11.3% | ||
| -$305.7M-7.6% | -$283.99M-12.3% | -$252.86M-9.3% | -$231.4M-8.2% | -$213.94M-11.5% | ||
| -$305.7M-7.6% | -$283.99M-12.3% | -$252.86M-9.3% | -$231.4M-8.2% | -$213.94M-11.5% | ||
| -35,299.7%-16,931pp | -18,369.1%-8,644pp | -9,725.3%-5,729pp | -3,995.9%-1,166pp | -2,830.3%-96.6pp | ||
| -$309.06M-7.5% | -$287.37M-12.1% | -$256.24M-9.2% | -$234.75M-8.1% | -$217.21M-11.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Celldex Therapeutics's revenue?
- Celldex Therapeutics (CLDX) generated $866.0K in revenue over the trailing twelve months, down 88.5% year over year.
- Is Celldex Therapeutics profitable?
- Celldex Therapeutics is not currently profitable: it reported a net loss of $283.6M over the trailing twelve months, a -32753.6% net margin.
- What is Celldex Therapeutics's earnings per share?
- Celldex Therapeutics's diluted EPS over the trailing twelve months is $-4.27.
- Where does Celldex Therapeutics's income statement data come from?
- Every line is extracted from Celldex Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
